Zinc therapy for night blindness in cystic fibrosis  by Tinley, Christopher G. et al.
Journal of Cystic Fibrosis 7 (2008) 333–335
www.elsevier.com/locate/jcfShort communication
Zinc therapy for night blindness in cystic fibrosis
Christopher G. Tinley a,⁎, Nicholas J. Withers b, Christopher D. Sheldon b,
Anthony G. Quinn a, Alan A. Jackson c
a West of England Eye Unit, Royal Devon and Exeter Hospital (Wonford), Barrack Road, Exeter, EX2 5DW, UK
b Royal Devon and Exeter Hospital (Wonford), UK
c Institute of Human Nutrition, Developmental Origins of Health and Disease Division, University of Southampton,
Southampton General Hospital (MP 113), Tremona Road, Southampton, SO16 6YD, UK
Received 21 September 2007; received in revised form 19 November 2007; accepted 27 November 2007
Available online 8 January 2008Abstract
This is the first report of a supplemented CF patient presenting with clinical vitamin A deficiency to be successfully treated with zinc therapy
alone. Therefore in addition to retinol supplementation, normalizing serum zinc levels may be important in maintaining the vitamin A status of CF
patients. The interactions and synergistic effects between the two micronutrients are discussed.
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Night blindness in cystic fibrosis (CF) is rare, but may occur
with vitamin A deficiency secondary to malabsorption [1].
Some patients develop nyctalopia despite oral vitamin A
supplementation [2,3]. We successfully treated such a patient
with zinc sulphate alone and discuss the interactions between
the two micronutrients.
2. Case report
A 23 year old woman with CF was referred to the West of
England Eye Unit with a two week history of ocular discomfort,
difficulty seeing in dim light and colours assuming a green hue.
She was diagnosed with CF after presenting with meconium
ileus at 5 weeks of age (δF508 homozygote; sweat test Na
+104-
mmol/l), and had complications of adhesions requiring small
bowel resection as a child. In addition, she had cystic fibrosis-
related diabetes and severe respiratory impairment (FeV1 1.45 l,
FVC 1.97 l, PEF 280 l/min). Medical therapy at the time⁎ Corresponding author. Tel./fax: +44 1392 361153.
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doi:10.1016/j.jcf.2007.11.005consisted of oral prednisolone 10 mg, nebulised colomycin,
budesonide/formoterol fumarate inhalations, and insulin. Daily
oral supplementation included pancreatic enzymes, vitamin A
4000 IU, vitamin D 400 IU, multivitamins (vitamin A 5000 IU,
vitamin D3 600 IU, vitamin B1,2&3 ,vitamin C), vitamin E
400 IU, vitamin K 10 mg, ferrous sulphate 400 mg, and calcium
carbonate/vitamin D3 400 IU.
Visual acuity was 6/9 in each eye and there was no red–green
colour deficit. Focal areas of keratinisation (Bitot's spots) were
present on the interpalpebral conjunctivae with bilateral diffuse
corneal punctate epitheliopathy. Posterior segment examination
was normal. Serum vitamin A was low, 0.2 mg/l (1.5–4.2), but
had been less than 0.7 mg/l for the previous 5 years, despite
compliance with vitamin supplementation. A serological zinc
deficiency was also present, with levels measured at 8.1 µmol/l
(11.4–24.8). There was no evidence of fat malabsorption
clinically, but her BMI was low (19.6), and there were
deficiencies in other fat soluble vitamins (vitamin D 7.5 ng/ml
(25–50), vitamin E 6.4 mg/l (11.6–37.1), normal clotting
profile). No fat studies on stool were performed however.
Hepatic enzymes were mildly deranged (ALT 47U/l (5–31),
ALP 108U/l (34–102), but synthetic function (bilirubin, albu-
min) was normal.d by Elsevier B.V. All rights reserved.
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no response to rod stimulation with a dim blue flash (Fig. 1A)
and reduced A and B wave amplitudes to a bright white flash in
dark-adapted conditions. Cone responses were normal. Treat-
ment was commenced with oral zinc sulphate 220 mg tds alone
(Zincomed®, 50 mg elemental zinc per 220 mg tablet). Within
1 week there was a dramatic improvement in the symptoms of
nyctalopia and signs of xerophthalmia, with recovery of serum
zinc levels (12.1 µmol/l). Serum vitamin A levels remained low
however, at 0.2 mg/l. Repeat dark-adapted ERG demonstrated a
clear rod response, indicating full restoration of rod photo-
receptor function (Fig. 1B).
3. Comment
Zinc is absorbed by enterocytes in the proximal small
intestine, and zinc deficiency has been associated with
malabsorption syndromes such as CF [4]. In CF, unabsorbed
fat specifically interferes with the re-absorption of endogenous
zinc [5], and this, together with prior small bowel resection,
may have contributed to the zinc deficiency in this case.
Furthermore, iron supplementation has been shown to inhibit
zinc absorption in the human small intestine [6].
The knowledge of zinc metabolism in the eye is fragmentary.
Much of the evidence for its role in retinal function comes from
interaction studies with other nutrients, a few naturally
occurring diseases and in vitro studies [4]. It is known that
zinc interacts with taurine and vitamin A in the retina, modifies
plasma membranes in the photoreceptors, regulates the light-
rhodopsin reaction within the photoreceptor, modulates synap-
tic transmission and serves as an anti-oxidant in both the retinal
pigment epithelium and retina [4]. Although zinc deficiency
was previously thought to impair retinol dehydrogenase
activity, it is now known that this enzyme is zinc independent
[7]. However, numerous other enzymes important in the visualFig. 1cycle may be zinc dependent. Zinc deficiency can depress the
hepatic synthesis of retinol-binding protein (RBP) and lead to
lower concentrations of RBP in the plasma, which is required
for mobilization of retinol from the liver [8]. In addition, there
may be a specific role of zinc in the conversion of β-carotene to
retinol via the enzyme 15-15 dioxygenase [9].
Zinc deficiency has been implicated in rod dysfunction and a
patient with liver cirrhosis and night blindness was reported to
show an improvement in rod ERG's after treatment with oral
cholagogues, and this was attributed to recovery of deficient
serum zinc levels and liver function [10]. Morrison et al.
demonstrated a rapid recovery in cirrhotic patients with impaired
dark adaptation and low serum zinc levels on zinc supplementa-
tion alone [11]. There appears to be an interaction between zinc
and vitamin A in patients suffering from various pathological
conditions that severely compromise hepatic function, such as
alcoholic cirrhosis, CF and idiopathic haemochromatosis [8]. In
humans, cross-sectional studies have more often than not shown
a weak linkage between vitamin A and zinc status [8]. However
randomized trials have failed to show a consistent effect of zinc
supplementation on vitamin A status [8]. Circulating zinc and
vitamin A levels appear unrelated in well-nourished states, but
tend to co-vary in marginally nourished individuals, with co-
existing zinc and vitamin A deficiencies [8]. Intestinal vitamin A
malabsorption may be due to specific effects of zinc deficiency
beyond any generalized effects of malnutrition. Thus zinc
deficiency may result in a secondary vitamin A deficiency that is
reflected in low serum vitamin A concentrations [7]. Conversely,
severe vitamin A deficiency may reduce absorption and
lymphatic transport of zinc by altering the synthesis of zinc-
dependent binding protein [8].
Low serum vitamin A levels occur frequently in clinically
stable, retinol-supplemented CF patients [12]. However due to
the absence of a statistical correlation between hepatic and
plasma levels of retinol in CF, serum retinol does not reflect.
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from liver storage tissues has been proposed as the reason for
this, which indeed may be due to a co-existing zinc deficiency.
Thus even in the presence of adequate hepatic vitamin A
reserves, night blindness may occur when zinc deficiency exists
[7]. However, to date, studies regarding zinc-related vitamin A
deficiency in CF have been inconclusive [8].
A proportion of CF patients on oral vitamin A supplementa-
tion have abnormal dark adaptation and conjunctival xerosis
due to vitamin A deficiency [13]. Some patients with abnormal
dark adaptation do not respond to increasing their vitamin A
intake until zinc supplements are administered [13]. In CF
patients with vitamin A deficiency, therapy can be commenced
with intramuscular water soluble vitamin A 30 000 IU [14].
However in this case it was difficult to source locally.
Furthermore, high-dose vitamin A supplementation should be
given with caution due to its potential for hepatotoxicity and
risk of intracranial hypertension [12]. It was previously thought
that among zinc deficient subjects, zinc on its own may not
resolve night blindness or poor dark adaptation, but acts only to
potentiate vitamin A in preventing night blindness [7]. This is
the first report of a supplemented CF patient presenting with
clinical vitamin A deficiency to be successfully treated with
zinc supplementation alone.
Therefore in addition to retinol supplementation, normal-
ising serum zinc levels may be important in maintaining the
vitamin A status of CF patients. A routine enquiry as to whether
patients were experiencing problems seeing at night would
seem worthwhile. The European consensus on nutrition in
patients with CF recommends up to 10 000 IU daily of fat
soluble vitamin A, to maintain serum concentrations within the
normal range. If serum concentrations are found to be low,
despite supplementation to these levels, consideration should be
given to patient compliance and zinc levels should be measured
[15].
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